TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07152379: Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs

Sponsor: Cerus Corporation · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 25 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,237,600

Rescue Site Savings

+$4,780,800

Unlock Full NCT07152379 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07152379 Rescue Dossier →